Study	Reason for exclusion
Aapro 2003	RCT of chemotherapy only (CD versus doxorubicin only) in women with advanced or recurrent disease. CRS was not performed. This study is included in the Cochrane review of chemotherapy for (non‐adjuvant) recurrent and metastatic endometrial cancer (Vale 2012).
Fleming 2004a	RCT of CD versus DP in women with advanced or recurrent endometrial cancer. Included patients with recurrent disease which was not amenable to surgery. This study is included in the Cochrane review of (non‐adjuvant) chemotherapy for advanced, recurrent and metastatic endometrial cancer (Vale 2012).
Fleming 2004b	RCT of CD versus CDP in women with advanced or recurrent endometrial cancer. Included patients with recurrent disease which was not amenable to surgery. This study is included in the Cochrane review of (non‐adjuvant) chemotherapy for advanced, recurrent and metastatic endometrial cancer (Vale 2012).
Gallion 2003	RCT of standard timing versus circadian timing of chemotherapy (CD) in women with advanced or recurrent disease. CRS was not performed. This study is included in the Cochrane review of chemotherapy for (non‐adjuvant) recurrent and metastatic endometrial cancer (Vale 2012).
Hogberg 2010	RCT of high‐risk endometrial cancer (HREC) participants (including 20% stage III participants) evaluating radiotherapy versus chemoradiation. This study is included in the Cochrane review of adjuvant chemotherapy for (any stage) endometrial cancer (Johnson 2011).
Kuoppala 2008	RCT of 156 HREC participants (including 20 stage IIIA participants [12%]) evaluating adjuvant radiotherapy versus sequential chemoradiation. This study is included in the Cochrane review of adjuvant chemotherapy for (any stage) endometrial cancer (Johnson 2011).
Mustea 2013	Feasibility study of chemoradiation in advanced disease, not a RCT.
Nomura 2011	RCT of cisplatin/docetaxel versus carboplatin/docetaxel versus carboplatin/paclitaxel in women with advanced or recurrent endometrial cancer with measurable disease (non‐adjuvant chemotherapy).
Wolfson 2007	This RCT was conducted in women with uterine sarcomas not endometrial carcinoma.

CD = cisplatin/doxorubicin; CDP = cisplatin/doxorubicin/paclitaxel; DP = doxorubicin/paclitaxel; CRS = cytoreductive surgery.